This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 800983.
Evolvable platform for programmable nanoparticle-based cancer therapies
(approved - launch on October 1, 2018)
We are consortium of 7 partners with shared goal of going far beyond the state of the art by creating entirely new nanoparticle design platform for cancer treatment capable of autonomously evolving both innovative and adaptive solutions.
Every partner in EVO-NANO has its own specific competencies and experience that is necessary to achieve the proposed objectives but with and overlap of knowledge that will enable an effective collaboration. EVO-NANO is organized around two research hubs: computing sciences and modelling (PFNS, UB, UWE and AAU) and experimental in vitro and in vivo cancer and nanoparticle research (IMDEA, VHIR and PCS). Partners with cross-disciplinary expertise are expected to work between these hubs to produce an integrated synthesis between in silico models and their material realizations.
© Copyright 2017. All Rights Reserved.